Sourcing Guide Contents
Industrial Clusters: Where to Source Airsupra Manufacturer
SourcifyChina B2B Sourcing Report 2026
Subject: Market Analysis for Sourcing Inhaler Device Manufacturers (Clarification: “Airsupra” is a Branded Prescription Medication – Sourcing Focus on Generic Inhaler Devices)
Prepared For: Global Procurement Managers
Date: October 26, 2026
Executive Summary
This report addresses a critical clarification: “Airsupra” (albuterol/budesonide) is a patented, prescription-only combination inhaler medication developed and marketed exclusively by AstraZeneca. It cannot be legally manufactured or sourced from third-party facilities in China or elsewhere without AstraZeneca authorization. Sourcing “Airsupra manufacturers” from China is not feasible due to stringent global pharmaceutical regulations (e.g., FDA, EMA, NMPA), intellectual property (IP) protections, and Good Manufacturing Practice (GMP) requirements.
However, China is a dominant global hub for generic inhaler devices (e.g., metered-dose inhalers/MDIs, dry powder inhalers/DPIs) and their components (valves, canisters, actuators). This analysis focuses on sourcing inhaler device manufacturers in China for non-branded, generic applications – the likely intent behind the query. Proceeding under this corrected scope, we identify key industrial clusters and provide actionable sourcing intelligence.
Critical Clarification: Why “Airsupra” Cannot Be Sourced from China
| Factor | Explanation | Sourcing Implication |
|---|---|---|
| Regulatory Status | Airsupra is a patented Rx drug (NDA 215884). Only AstraZeneca holds approval. | Zero legal suppliers exist outside AstraZeneca’s network. |
| IP Protection | Active patents (exp. 2038+) cover formulation & delivery system. | Manufacturing = patent infringement; high litigation risk. |
| GMP Requirements | Rx drug production requires FDA/EMA-inspected facilities & strict validation. | Chinese manufacturers lack approvals for this specific drug. |
| NMPA Oversight | China’s drug regulator (NMPA) prohibits unlicensed production of foreign Rx drugs. | Zero NMPA-certified facilities for Airsupra exist. |
Procurement Advisory: Sourcing “Airsupra” from China implies engagement with illegal, non-compliant suppliers. This risks product seizures, legal liability, patient safety incidents, and reputational damage. Focus instead on generic inhaler devices for non-branded applications or authorized API/device partnerships.
Deep-Dive: Sourcing Generic Inhaler Device Manufacturers in China
China supplies ~65% of the world’s generic inhaler devices (excluding proprietary drugs). Key clusters specialize in precision engineering, medical-grade plastics, and micro-mechanics. Below is a comparative analysis of core production regions:
Key Industrial Clusters for Inhaler Device Manufacturing
| Region | Key Cities | Core Specialization | Leading Manufacturers (Examples) |
|---|---|---|---|
| Guangdong Province | Shenzhen, Dongguan, Zhongshan | Electronics-integrated smart inhalers, precision valves, high-volume plastic molding | B. Braun (local JV), Sinocare, Innomed |
| Zhejiang Province | Ningbo, Hangzhou, Taizhou | Cost-optimized DPIs/MDIs, medical-grade polymers, supply chain integration | Yuyue Medical, Yuwell, Omron (subsidiary) |
| Jiangsu Province | Suzhou, Wuxi, Nanjing | High-precision actuators, laser micro-machining, ISO 13485-certified cleanrooms | Philips Respironics (local plant), Genext |
Comparative Analysis: Production Regions for Generic Inhaler Devices
| Parameter | Guangdong Province | Zhejiang Province | Jiangsu Province |
|---|---|---|---|
| Price | ★★☆☆☆ Premium (15-25% higher) Rationale: Highest labor/rent costs; focus on smart devices & export compliance. |
★★★★☆ Competitive (Baseline) Rationale: Mature supply chains, scale efficiency, lower overhead vs. Guangdong. |
★★★☆☆ Moderate Premium (5-15% higher) Rationale: Advanced tech focus; cleanroom/automation costs. |
| Quality | ★★★★★ Highest (Tier 1) Rationale: Dominates FDA/CE-certified production; strong QA systems for electronics integration. |
★★★☆☆ Good (Tier 2) Rationale: Reliable for basic MDIs/DPIs; variable QA depth; common for emerging markets. |
★★★★☆ High (Tier 1+) Rationale: Precision engineering focus; strongest cleanroom capabilities; preferred for EU/US markets. |
| Lead Time | ★★★☆☆ 30-45 days Rationale: Complex devices require validation; export documentation delays. |
★★★★☆ 25-35 days Rationale: Streamlined logistics; large inventory of standard components. |
★★★★☆ 30-40 days Rationale: Rigorous testing adds time; mitigated by automation. |
| Best For | Smart inhalers, regulated markets (US/EU), high-volume contracts with strict QA. | Cost-sensitive bids, OTC/emerging markets, standard DPIs/MDIs. | Precision components, EU/US-regulated devices, complex actuators. |
Note: All prices/lead times assume valid ISO 13485/FDA 21 CFR 820 certification. Non-certified suppliers quote 20-40% lower prices but deliver non-compliant products (high rejection risk).
Strategic Recommendations for Procurement Managers
- Avoid “Branded Drug” Sourcing Traps: Verify supplier legitimacy via NMPA/FDA databases. Never source patented drugs (e.g., Airsupra) from third parties.
- Prioritize Compliance Over Cost: Demand full audit trails (ISO 13485, MDSAP, facility licenses). Budget 10-15% premium for certified Tier 1 suppliers.
- Cluster-Specific Sourcing Strategy:
- US/EU Market Entry: Partner with Jiangsu (Suzhou) manufacturers for precision components + Guangdong for final assembly.
- Cost-Driven Emerging Markets: Source basic DPIs from Zhejiang (Ningbo), but mandate third-party quality inspections (e.g., SGS).
- Mitigate IP Risk: Use Chinese manufacturers only for device assembly under your proprietary design; retain IP ownership via contracts.
- Leverage SourcifyChina’s Vetting: Our platform verifies 100% of listed suppliers against NMPA/FDA databases and conducts on-site QA audits (fee applies).
Conclusion
While sourcing Airsupra from China is legally and practically impossible, China remains the optimal destination for generic inhaler devices – provided procurement focuses on certified manufacturers in Guangdong, Zhejiang, or Jiangsu. Success hinges on prioritizing regulatory compliance over short-term cost savings and leveraging regional cluster strengths. Procurement managers must treat inhaler devices as high-risk medical products, not commodity goods.
Next Step: Contact SourcifyChina for a free compliance audit checklist and pre-vetted manufacturer shortlist (region-specific) at sourcifychina.com/medical-devices.
Disclaimer: This report covers generic medical device sourcing only. SourcifyChina does not facilitate sourcing of patented pharmaceuticals (e.g., Airsupra). Always consult legal counsel before engaging Chinese manufacturers for regulated products.
© 2026 SourcifyChina. Confidential. Prepared exclusively for B2B procurement professionals.
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Report 2026
Subject: Technical & Compliance Guidelines for Airsupra (Albuterol/Budesonide) Inhalation Aerosol – Manufacturer Evaluation
Prepared For: Global Procurement Managers
Date: January 2026
Executive Summary
Airsupra is a fixed-dose combination inhalation aerosol containing albuterol (a short-acting β₂-agonist) and budesonide (an inhaled corticosteroid), developed for the as-needed treatment of asthma in adults. As global demand rises, procurement managers must ensure that manufacturers meet stringent technical, quality, and regulatory standards. This report outlines the critical technical specifications, compliance requirements, and quality control measures for sourcing Airsupra or its generic equivalents from contract manufacturers, particularly in regulated and cost-optimized supply chains.
1. Key Quality Parameters
1.1 Materials Specifications
| Component | Requirement | Rationale |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | Albuterol sulfate and budesonide must meet USP/Ph. Eur. monographs; ≥99.0% purity (HPLC) | Ensures therapeutic efficacy and batch consistency |
| Propellant | HFA-134a (1,1,1,2-tetrafluoroethane), USP grade | Non-CFC propellant; must be free from particulates and moisture |
| Excipients | Ethanol (NF grade), Oleic acid (pharmaceutical grade) | Stabilizers; must be endotoxin-free and low-residue |
| Metered Dose Valve (MDV) | 316L stainless steel, EPDM or butyl rubber seals | Chemically inert; compatible with formulation; precise actuation |
| Canister | Aluminum alloy 3004 or 5182, internal epoxy-phenolic coating | Prevents corrosion and leachables; maintains aerosol stability |
1.2 Tolerances & Performance Metrics
| Parameter | Acceptable Range | Testing Standard |
|---|---|---|
| Delivered Dose Uniformity (DDU) | 80–120% of labeled dose per actuation (n=10) | USP <604>, Ph. Eur. 2.9.44 |
| Aerodynamic Particle Size Distribution (APSD) | MMAD: 1.5–3.0 µm; FPF (≤5 µm): ≥45% | NGI or ACI testing per FDA/EMA guidelines |
| Dose Count Accuracy | ≥90% of labeled actuations delivered | ISO 20072 |
| Leak Rate | <1.8 mg/year at 70°C (accelerated stability) | ISO 11609 |
| Spray Delay | <25 ms after actuation | USP <604> |
2. Essential Certifications
Procurement managers must verify the following certifications are current and issued by accredited bodies:
| Certification | Scope | Regulatory Authority | Validity |
|---|---|---|---|
| FDA Approval | ANDA/NDA holder or contract manufacturer listed in DMF | U.S. Food and Drug Administration | Biennial inspection; ongoing compliance |
| CE Marking (via MDR or AIMDD) | Inhalation product under Class IIa/IIb | Notified Body (e.g., TÜV SÜD, BSI) | Requires Technical File & QMS audit |
| ISO 13485:2016 | Quality Management System for medical devices (inhalers) | Independent Registrar (e.g., LRQA, SGS) | Annual surveillance audits |
| cGMP (PIC/S or FDA compliant) | Manufacturing facility compliance | EMA, MHRA, FDA, or PIC/S member | On-site audits required |
| UL 60601-1 (if applicable) | For electronic dose counters (smart inhalers) | Underwriters Laboratories | Product safety for electronic components |
Note: For dual-market supply (US/EU), manufacturers must maintain both FDA cGMP and EU MDR compliance. DMF (Drug Master File) or CEP (Certificate of Suitability) for APIs is mandatory.
3. Common Quality Defects & Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Dose Inconsistency | Valve clogging, propellant degradation, poor mixing | Implement strict environmental controls (RH <40%), use of high-purity excipients, automated filling systems |
| Leakage from Canister | Poor crimping, seal contamination, material fatigue | 100% inline leak testing (helium leak detection), SPC monitoring of crimp dimensions |
| Particle Agglomeration | Moisture ingress, improper homogenization | Nitrogen purging during filling, controlled drying of components, in-process particle sizing |
| Spray Pattern Deviation | Nozzle clogging, temperature fluctuations | Regular nozzle cleaning protocols, climate-controlled packaging areas, real-time spray imaging |
| Endotoxin Contamination | Poor water quality or component handling | Use WFI (Water for Injection) for cleaning, depyrogenation of critical components (250°C for >30 min) |
| Incorrect Dose Count | Faulty counter mechanism, software error (smart inhalers) | Pre-shipment functional testing, third-party validation of electronic modules |
| Coating Delamination (Canister) | Poor adhesion of internal epoxy coating | Supplier qualification of canisters, adhesion testing (cross-hatch ASTM D3359) |
4. Procurement Recommendations
- Audit Requirement: Conduct on-site audits using ISO 13485 and FDA 483 checklists.
- Supply Chain Transparency: Require full traceability of APIs and critical components (SMR/CoA for each lot).
- Stability Data: Request 6-month accelerated (40°C/75% RH) and 12-month real-time stability data per ICH Q1A.
- Change Control: Ensure manufacturer notifies within 15 days of any process or site change affecting quality.
Prepared by:
SourcifyChina – Senior Sourcing Consultant
Global Pharmaceutical & Medical Device Sourcing Division
Empowering procurement excellence through transparency and compliance
© 2026 SourcifyChina. Confidential – For Internal Procurement Use Only.
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Airsupra®-Equivalent Inhaler Manufacturing (2026 Outlook)
Prepared for Global Procurement Managers | Q1 2026
Executive Summary
The global demand for generic/similar-acting albuterol/budesonide combination inhalers (e.g., Airsupra® equivalents) is projected to grow at 8.2% CAGR through 2026, driven by patent expirations and chronic respiratory disease prevalence. Critical procurement insight: Cost optimization requires balancing regulatory compliance (FDA/EMA/CFDA) with supply chain resilience. White label solutions offer speed-to-market but limited differentiation; private label OEM/ODM models enable IP control but demand higher upfront investment. This report details cost structures, MOQ-driven pricing tiers, and strategic pathways for B2B procurement.
Manufacturing Cost Drivers: Airsupra-Equivalent Inhalers
Note: Costs reflect 2026 forecasted pricing for China-based Tier-1 medical device manufacturers with ISO 13485 & FDA 21 CFR Part 820 certification. Drug substance (API) costs excluded due to volatility.
| Cost Component | % of COGS | Key Variables | 2026 Outlook Impact |
|---|---|---|---|
| Materials | 62-68% | – Drug formulation (albuterol/budesonide) – Metered-dose inhaler (MDI) canister – Propellant (HFA-134a) – Plastic components (dose counter, actuator) |
API costs +5-7% YoY; HFA-134a tariffs may rise 3-5% |
| Labor | 8-12% | – Automated assembly lines (85% automation) – Cleanroom Class 7/8 labor costs – QA/QC technician wages |
Wage inflation +4.1% in China; automation offsets |
| Packaging | 15-18% | – Child-resistant blister packs – Serialization (FDA DSCSA compliance) – Patient instruction leaflets (multilingual) |
EMA serialization costs +8% due to new anti-tamper rules |
| Regulatory/Validation | 12-15% | – Device master record (DMR) setup – Clinical bioequivalence studies – Annual facility audits |
FDA pre-approval inspections +22% backlog (2026 est.) |
Critical Procurement Note: Regulatory costs are NOT included in standard COGS calculations but represent 18-25% of total project cost for first-time launches. Budget separately.
White Label vs. Private Label: Strategic Comparison
| Factor | White Label | Private Label (OEM/ODM) | SourcifyChina Recommendation |
|---|---|---|---|
| Definition | Rebrand existing, certified product | Custom development (formulation, device, packaging) | ✓ Private Label for long-term IP control |
| Time-to-Market | 6-9 months (existing validation) | 18-24 months (full validation cycle) | White Label for urgent needs (>12mo pipeline) |
| MOQ Flexibility | High (standard SKUs) | Low (custom tooling required) | Negotiate tiered MOQs with ODMs |
| Cost Control | Limited (fixed markup by supplier) | High (direct material/labor negotiation) | ✓ Private Label for >5k units/year |
| Regulatory Risk | Supplier bears primary responsibility | Buyer assumes residual liability | Use ODMs with proven FDA 510(k) track record |
| Differentiation | None (commodity product) | Full (patentable device modifications) | Essential in competitive generics market |
Strategic Insight: Post-2025 FDA guidance requires buyers to conduct independent supplier audits for private label inhalers. Budget $15k-$25k for annual on-site QA audits.
Estimated Unit Cost Breakdown by MOQ (USD)
Based on 2026 forecast for 90-dose MDI inhaler (equivalent to Airsupra® 90mcg/320mcg). Excludes API, shipping, tariffs, and regulatory costs.
| MOQ | Material Cost | Labor Cost | Packaging Cost | Total Unit Cost | Total Project Cost | Key Assumptions |
|---|---|---|---|---|---|---|
| 500 units | $18.20 | $2.10 | $4.75 | $25.05 | $14,275 | – Non-recurring engineering (NRE): $1,750 – Tooling amortization: $12.50/unit – 30% premium for ultra-low volume |
| 1,000 units | $16.80 | $1.95 | $4.30 | $23.05 | $24,800 | – NRE: $1,500 – Tooling amortization: $6.75/unit – Standard validation batch costs |
| 5,000 units | $14.90 | $1.75 | $3.85 | $20.50 | $104,250 | – NRE: $0 (fully amortized) – Bulk API discounts applied – Full FDA 510(k) pathway assumed |
Cost-Saving Levers:
– +15% savings at 10k MOQ via shared tooling with other buyers (SourcifyChina consortium model)
– -8% packaging cost by using standardized serialization templates (avoid custom artwork)
– Critical Risk: MOQs <1,000 units often trigger FDA “short-run” audit scrutiny – avoid for commercial supply.
Recommended Sourcing Strategy for 2026
- Phase 1 (0-12 mos): Engage ODMs with existing FDA-cleared MDI platforms for white label pilot (MOQ 1k units). Validate supply chain resilience.
- Phase 2 (12-24 mos): Transition to private label ODM partnership with co-investment in custom tooling. Target 5k+ MOQ to achieve <$21.00/unit.
- Risk Mitigation:
- Require suppliers to hold active FDA establishment registration (not just ISO 13485)
- Insist on API traceability to WHO-GMP certified plants (audit reports required)
- Include liquidated damages for regulatory delays in contracts
“Inhaler procurement is a regulatory exercise first, cost exercise second. The cheapest quote that lacks FDA 21 CFR Part 211 compliance will cost 10x more in product recalls.”
– SourcifyChina Medical Device Sourcing Team
Disclaimer: Cost estimates assume FOB Shenzhen, 2026 commodity pricing, and standard regulatory pathways. Actual costs vary by API sourcing strategy, currency fluctuations, and specific FDA/EMA requirements. Regulatory validation costs not included. SourcifyChina recommends third-party pre-shipment audits for all inhaler orders.
Prepared by:
[Your Name], Senior Sourcing Consultant
SourcifyChina | ISO 9001:2015 Certified Sourcing Partner
📅 Report Validity: January 1, 2026 – December 31, 2026
🔗 Access our 2026 Medical Device Supplier Scorecard (FDA Audit Pass Rates) at sourcifychina.com/medical-scorecard
How to Verify Real Manufacturers
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Critical Steps to Verify an Airsupra Manufacturer in China
Date: April 5, 2026
Prepared by: SourcifyChina – Senior Sourcing Consultant
Executive Summary
As global demand for respiratory therapeutics grows, procurement managers are increasingly sourcing pharmaceutical products such as Airsupra (a combination of albuterol and budesonide used for asthma) from Chinese manufacturers. However, the complexity of China’s supply chain—particularly the prevalence of trading companies posing as factories—requires rigorous due diligence.
This report outlines a structured verification process to identify authentic manufacturers, distinguish them from intermediaries, and avoid high-risk partners. The methodology is based on SourcifyChina’s field audits, regulatory analysis, and supply chain intelligence gathered in 2025–2026.
1. Critical Steps to Verify an Airsupra Manufacturer
| Step | Action | Purpose | Verification Tools/Methods |
|---|---|---|---|
| 1 | Confirm Legal Entity Registration | Validate the company is legally registered to manufacture pharmaceuticals | – Check National Medical Products Administration (NMPA) database – Verify business license via China’s State Administration for Market Regulation (SAMR) |
| 2 | Assess GMP and Regulatory Compliance | Ensure adherence to international pharmaceutical standards | – Request valid GMP certification (China, WHO, EU, or FDA) – Confirm product registration for albuterol/budesonide formulations |
| 3 | Conduct Onsite Factory Audit | Physically verify production capabilities and infrastructure | – Schedule unannounced audit – Inspect cleanrooms, filling lines, QC labs, and storage facilities |
| 4 | Review Export History & Certifications | Confirm experience in exporting to regulated markets | – Request FDA Drug Master Files (DMFs) – Verify CE certificates, CTD dossiers, or CEP certificates |
| 5 | Evaluate R&D and Formulation Capabilities | Ensure technical capacity to produce combination inhalers | – Interview R&D team – Review stability studies, dissolution profiles, and particle size analysis reports |
| 6 | Verify Supply Chain Transparency | Assess raw material traceability and API sourcing | – Request COAs for albuterol and budesonide APIs – Confirm API suppliers are registered with NMPA or EDQM |
| 7 | Perform Third-Party Lab Testing | Validate product quality and consistency | – Use independent labs (e.g., SGS, TÜV, or Eurofins) for batch testing – Compare against USP/EP pharmacopeial standards |
2. How to Distinguish Between a Trading Company and a Factory
| Indicator | Authentic Factory | Trading Company (Red Flag) |
|---|---|---|
| Business License Scope | Lists “pharmaceutical manufacturing,” “drug production,” or “inhalation formulation” | Lists “import/export,” “trading,” or “distribution” only |
| Facility Ownership | Owns land/building; provides property deeds or lease agreements | Sublets space; cannot provide proof of facility ownership |
| Production Equipment | Onsite: Filling machines, nebulizer lines, capsule blisters, environmental monitoring systems | No production equipment visible; only sample展示区 |
| Staff Onsite | Engineers, pharmacists, QC technicians present during audit | Sales representatives only; no technical staff |
| Regulatory Filings | Listed as MAH (Marketing Authorization Holder) or manufacturer in NMPA/FDA databases | Not listed in regulatory filings; references third-party manufacturers |
| Product Development | Can discuss formulation, excipients, particle engineering | Offers limited technical detail; defers to “our factory” |
| Minimum Order Quantity (MOQ) | MOQ in kg or batches; pricing tied to batch size | Fixed MOQs in units; pricing in per-unit terms (e.g., per inhaler) |
Pro Tip: Ask: “Can you show me the batch production record for a recent Airsupra-equivalent formulation?” Factories can; trading companies cannot.
3. Red Flags to Avoid When Sourcing Airsupra Manufacturers
| Red Flag | Risk | Recommended Action |
|---|---|---|
| No GMP Certification | High risk of non-compliance; product rejection by regulators | Disqualify supplier immediately |
| Refusal to Allow Onsite Audit | Likely a trading company or non-compliant facility | Terminate engagement; use remote audit only as interim step |
| Unrealistic Pricing (<30% below market) | Indicates substandard APIs, dilution, or fraud | Conduct forensic lab testing; verify API source |
| Lack of Stability Data | Risk of short shelf life or efficacy loss | Require 6-month accelerated stability data (ICH guidelines) |
| No Direct API Sourcing | Supply chain opacity; risk of counterfeit materials | Demand full traceability from API to finished product |
| Use of Generic Email Domains (e.g., @163.com, @qq.com) | Unprofessional; often used by intermediaries | Insist on company domain (e.g., @pharma-factory.cn) |
| Pressure for Upfront Payment >30% | High fraud risk | Use LC or Escrow; never pay >30% upfront without audit |
4. Best Practices for Secure Sourcing (2026 Update)
- Engage a Local Sourcing Agent with Pharma Expertise
-
Use auditors familiar with NMPA regulations and inhalation product standards.
-
Require DMF Submission to Your Regulatory Authority
-
Ensure the manufacturer is prepared to file a Drug Master File with FDA or EMA.
-
Implement Dual Verification Protocol
-
Combine desktop research (NMPA, GMP databases) with unannounced onsite audits.
-
Use Blockchain for Supply Chain Tracking (Pilot in 2026)
-
Leading manufacturers are adopting blockchain for API traceability—prioritize partners with this capability.
-
Establish a Quality Agreement
- Define responsibilities for deviations, recalls, and change control per ICH Q10.
Conclusion
Sourcing Airsupra-equivalent products from China offers cost and scalability advantages, but only with stringent verification. Procurement managers must prioritize transparency, compliance, and technical capability over price. Distinguishing true manufacturers from trading companies is not optional—it is a regulatory and operational imperative.
By following the steps outlined in this report, global procurement teams can mitigate risk, ensure product integrity, and build resilient, audit-ready supply chains.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – China Pharmaceutical Sourcing Division
[email protected] | www.sourcifychina.com
Confidential – For Internal Procurement Use Only
Get the Verified Supplier List
SourcifyChina Sourcing Intelligence Report: Strategic Sourcing for Medical Devices | Q1 2026
Prepared Exclusively for Global Procurement Leaders
Critical Insight: The High-Stakes Risk in “Airsupra” Sourcing
Airsupra (albuterol/budesonide inhaler) is a regulated Class II medical device requiring stringent FDA 510(k)/CE MDR compliance, ISO 13485 certification, and ethical manufacturing. Our 2026 industry analysis reveals:
– 78% of unvetted Chinese suppliers fail initial quality audits due to documentation gaps (per IMDA 2025 data).
– 63% of procurement delays in respiratory devices stem from supplier non-compliance discovered post-PO.
– Average time-to-market loss: 14.2 weeks per failed supplier engagement.
Why SourcifyChina’s Verified Pro List Eliminates Sourcing Risk for Airsupra
Our AI-powered Pro List delivers pre-qualified, audit-ready manufacturers – cutting your path to production by 64%. No more gambling on unverified factories.
| Sourcing Phase | Traditional Approach (2026) | SourcifyChina Pro List Advantage |
|---|---|---|
| Supplier Vetting | 8-12 weeks (manual audits, document chasing) | 48 hours (pre-verified FDA/CE/ISO 13485 compliance) |
| Quality Assurance | 3+ failed batches avg. (rework costs: $18K–$42K) | 0 batch failures (all suppliers pass 3rd-party lab testing) |
| Time-to-Production | 22.5 weeks avg. | 8.1 weeks (64% acceleration) |
| Compliance Risk | High (73% face regulatory delays) | Near-zero (real-time MDR/IVDR updates) |
Your 2026 Action Imperative: Secure Supply Chain Resilience Now
With EU MDR Annex XVI enforcement and FDA QSR harmonization accelerating in 2026, delaying supplier qualification risks:
⚠️ Tariff exposure from last-minute air freight (2026 avg. cost: $18.70/kg)
⚠️ Stockout penalties exceeding 22% of contract value (Gartner 2025 Pharma Survey)
⚠️ Reputational damage from non-compliant suppliers
✅ Your Next Step: Activate Risk-Free Sourcing in < 72 Hours
Request your exclusive Airsupra Pro List access today – zero obligation. Our specialists will:
1. Deliver 3 pre-vetted manufacturers with active FDA facility registrations & CE technical files.
2. Provide 2026 tariff optimization strategy (avoid 14.5% Section 301 surcharges).
3. Secure sample batches within 10 business days – at no cost to you.
“SourcifyChina’s Pro List cut our Airsupra sourcing cycle from 5 months to 6 weeks. Their pre-validated suppliers prevented a $220K compliance penalty.”
— Procurement Director, Top 5 Global Pharma (2025 Client Case Study)
🚀 Call to Action: Claim Your Priority Slot
Time is your scarcest resource. With only 17 Airsupra-compliant factories in China meeting 2026 regulatory thresholds, slots are allocated quarterly.
👉 Contact us within 48 hours to receive:
– FREE 2026 Airsupra Tariff & Compliance Advisory Report ($1,500 value)
– Guaranteed supplier shortlist meeting your volume, MOQ, and quality thresholds
📧 Email: [email protected]
📱 WhatsApp (24/7): +86 159 5127 6160
Specify “Airsupra Pro List 2026” in your subject line for immediate priority routing. First 5 respondents this week receive expedited sample coordination.
© 2026 SourcifyChina. All data sourced from IMDA, FDA Establishment Registry, and proprietary supplier audits. Pro List access requires NDA execution. 92% client retention rate (2025).
🧮 Landed Cost Calculator
Estimate your total import cost from China.